Abstracts tagged "TNF-blocking Antibody"

Abstract Number: 1308 • ACR Convergence 2023
Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study
Clementina López Medina¹, Jerusalem Calvo², Maria del Carmen Abalos-Aguilera³, Francisco Cepas⁴, Chamaida Plasencia-Rodríguez⁵, Ana Martinez Feito⁶, Alejandro Balsa⁵, Regina Faré-García⁷, Antonio Juan Mas⁷, Virginia Ruiz-Esquide⁸, Luis Sainz-Comas⁹, César Díaz-Torné⁹, Javier Godoy¹⁰, Isabel Anon Onate¹¹, Natalia Mena Vazquez¹², SARA MANRIQUE¹³, Marina soledad Moreno Garcia¹⁴, Rafaela Ortega Castro¹⁵ and Alejandro Escudero-Contreras¹⁶, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁴Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ⁷Son Llazter University Hospital, Palma, Spain, ⁸Hospital Clinic, Rheumatology, Barcelona, Spain, ⁹Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Jaen University Hospital, Jaen, Spain, ¹¹Hospital Universitario de Jaen, Jaen, Spain, ¹²IBIMA, Málaga, Spain, ¹³Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ¹⁴Hospital Miguel Servet, Zaragoza, Spain, ¹⁵Hospital Reina Sofía, Cordoba, Spain, ¹⁶Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain
Background/Purpose: Rheumatoid Factor (RF) is an antibody against the Fc fragment of IgG that contributes to the Rheumatoid Arthritis (RA) development. RF can bind the…
Abstract Number: 1316 • ACR Convergence 2023
Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis
Ana Martinez Feito¹, Chamaida Plasencia-Rodríguez², Marta Novella-Navarro², Johanna E. Gehin³, Borja Hernandez-Breijo⁴, Claudia M.Brenis⁵, Alejandro Villalba⁶, Elisa Fernandez-Fernandez⁴, Irene Monjo⁷, Dora Pascual-Salcedo⁸, Pilar Nozal⁹ and Alejandro Balsa², ¹Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴La Paz University Hospital, Madrid, Spain, ⁵VIB-UGent Inflammation Research Center Gent, Belgium, Gent, Belgium, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁷University Hospital La Paz, Madrid, Spain, ⁸Immuno-Rheumatology Research Group, La Paz University Hospital, Madrid, Spain, ⁹Immunology Unit in La Paz University Hospital-Idipaz, Madrid, Spain
Background/Purpose: Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity. A significantly lower efficacy of TNF inhibitors (TNFi)…
Abstract Number: 1554 • ACR Convergence 2023
Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study
Audrey Hermant¹, Yann Nguyen², Fleur Cohen³, Antoine Baudet⁴, Alban DEROUX⁵, Vincent Poindron⁶, Cécile-Audrey Durel⁷, Nicolas Girszyn⁸, Noémie Le Gouellec⁹, Benedicte Rouviere¹⁰, Helder Gil¹¹, Francois Maurier¹², Nicolas Noel¹³, Loic Raffray¹⁴, Hubert De Boysson¹⁵, Benoit Faucher¹⁶, Bertrand Godeau¹⁷, Pierre Lozach¹⁸, Claude Bachmeyer¹⁹, Alice Berezne⁴, Gilles Blaison²⁰, Brice Castel²¹, Guillaume Gondran²², Matthieu Groh²³, Stéphane Giorgiutti²⁴, Jeremy Keraen²⁵, Julie Magnant²⁶, Sebastien Monnier²⁷, Philippe Blanche²⁸, Dominique Monnet²⁹, Antoine Brezin²⁹ and Benjamin Terrier³⁰, ¹Hopital Cochin, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Sorbonne Université, Paris, France, ⁴CH Annecy, Annecy, France, ⁵CHU de Grenoble, Grenoble, France, ⁶Strasbourg, Strasbourg, France, ⁷CHU Lyon, Lyon, France, ⁸Rouen, Rouen, France, ⁹CH Valenciennes, Valenciennes, France, ¹⁰CHU Brest, Brest, France, ¹¹CHU Besancon, Besançon, France, ¹²CH Metz, Metz, France, ¹³CHU Bicetre, Le Kremlin-Bicêtre, France, ¹⁴CHU la Réunion, La Réunion, France, ¹⁵CHU Caen, Caen, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Henri Mondor, Créteil, France, ¹⁸CH Le Mans, Le Mans, France, ¹⁹CHU Tenon, Paris, France, ²⁰Hôpital Louis PASTEUR, Colmar, France, ²¹CH Tarbes, Tarbes, France, ²²CHU Limoges, Limoges, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CH Quimper, Quimper, France, ²⁶CHU Tours, Tours, France, ²⁷CH Versailles, Versailles, France, ²⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁹CHU Cochin, Paris, France, ³⁰Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The management of severe ocular involvement in Behçet's disease (BD) is an important issue with major functional implications due to the risk of blindness.…
Abstract Number: 2054 • ACR Convergence 2023
Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
Ilaria Maccora¹, Catherine Guly², Lavinia Sanfilippo³, sara Soldovieri⁴, Cinzia De Libero⁵, Athimalaipet V Ramanan⁶ and Gabriele Simonini⁷, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Ophthalmology Unit, Bristol Eye Hospital, Bristol, United Kingdom, ³Meyer Children's Hospital IRCCC, Florence, Italy, ⁴Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, ⁶Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, ⁷Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: Childhood Chronic Idiopathic Uveitis (cCIU) is a severe ocular condition that accounts for the 40% of all uveitis in children. Its timely and proper…
Abstract Number: 2148 • ACR Convergence 2023
Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
Josef S Smolen¹, Peter C. Taylor², Yoshiya Tanaka³, Carlos Cara⁴, Bernard Lauwerys⁵, Ricardo Xavier⁶, Jeffrey R Curtis⁷, Ted R Mikuls⁸ and Michael Weinblatt⁹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴UCB Pharma, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
Abstract Number: 2161 • ACR Convergence 2023
Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501
Vincent Chow, Muhan Zhou, Daniel Mytych, Alexander Colbert, Mieke Jill Miller, Iwona Wala and Waldemar Radziszewski, Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 has been developed as a biosimilar for Humira® (adalimumab), a fully human monoclonal antibody targeting tumor necrosis factor alpha (TNFα). ABP 501…
Abstract Number: 0359 • ACR Convergence 2023
Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
Chelsea Vallejos¹, Jennifer Cooper² and Ingrid Pan¹, ¹Children's Hospital Colorado, Aurora, CO, ²University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Adalimumab therapeutic drug monitoring (TDM) using established trough concentrations is not standard practice in JIA patients, unlike IBD. No specific guidelines outline a therapeutic…
Abstract Number: 2244 • ACR Convergence 2023
Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis
Dalifer Freites Núñez¹, Maria Rodriguez Laguna¹, Cristina Hormigos martín¹, zulema Rosales², Leticia Leon³, Gloria Candelas¹, Daniel Rubio⁴, Jose Otazu¹, Benjamin Fernandez¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ⁴Complutense University, Madrid, Spain
Background/Purpose: Biological and targeted synthetic therapies (ts/bDMARDs) have transformed the management ofPsoriatic arthritis (PsA).However, PsA might experience ts/bDMARD failure, (mainly due to inefficacy), and switching…
Abstract Number: 0360 • ACR Convergence 2023
Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial
Bastiaan van Dijk¹, Sytske Anne Bergstra¹, Merlijn van den Berg², Dieneke Schonenberg-Meinema², Lisette van Suijlekom-Smit², Marion van Rossum³, Yvonne Koopman⁴, Rebecca Ten Cate¹, CF Allaart¹, Danielle Brinkman¹ and Petra Hissink Muller¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center | Reade, Amstelveen, Netherlands, ⁴HagaZiekenhuis Juliana Children's Hospital, The Hague, Netherlands
Background/Purpose: The relation between etanercept dose and clinical outcomes of juvenile idiopathic arthritis (JIA) is unclear. Most studies only evaluated doses up to 0.8 mg/kg/week…
Abstract Number: 0419 • ACR Convergence 2023
No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors
Romy Hansildaar¹, Reinder Raadsen¹, Maaike Heslinga² and Michael Nurmohamed², ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-fold higher risk of venous thromboembolism (VTE) compared with the general population. The immune system and hemostatic…
Abstract Number: 0515 • ACR Convergence 2023
Dose Adjustment of Tumor Necrosis Factor Inhibitors Does Not Correlated with Radiographic Progression in Patients with Ankylosing Spondylitis
Bon San Koo¹, Seo Young Park², Ji Hui Shin³, Seunghun lee³, kyung bin Joo³ and Tae-Hwan Kim⁴, ¹Inje University Seoul Paik Hospital, Seoul, South Korea, ²Korea National Open University, Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Among patients with ankylosing spondylitis (AS) treated with tumor necrosis factor (TNF) inhibitors, tapering the dose of TNF inhibitors may be considered for patients…
Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Francois Maillet¹, Yann Nguyen², Olivier Espitia³, Laurent Perard⁴, Carlo Salvarani⁵, Etienne Rivière⁶, Cécile-Audrey Durel⁷, Philippe GUILPAIN⁸, Luc Mouthon⁹, Anna Kernder¹⁰, Javier Loricera¹¹, Pascal Cohen¹², Isabelle Melki¹³, Claire De Moreuil¹⁴, Nicolas Limal¹⁵, Arsène Mekinian¹⁶, Nathalie Costedoat-Chalumeau¹⁷, Nathalie Morel¹², Jonathan Boutemy¹⁸, Loic Raffray¹⁹, Jean-Sébastien Allain²⁰, Valerie Devauchelle²¹, Isabelle Kone-Paut²², Marc Fabre²³, Marie Durel²⁴, Antoine Dossier²⁵, Sébastien Abad²⁶, Marcella Visentini²⁷, Adrien Bigot²⁸, Halil Yildiz²⁹, Olivier Fain³⁰, Maxime Samson³¹, Guillaume Gondran³², Vered Abitbol¹ and Benjamin Terrier³³, ¹Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³CHU de Nantes, Nantes, France, ⁴CH Saint Hoseph Saint Luc, Lyon, France, ⁵Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁶CHU Bordeaux, Bordeaux, France, ⁷CHU Lyon, Lyon, France, ⁸University of Montpellier, Montpellier, France, ⁹Hopital Cochin - Paris University, Paris, France, ¹⁰HHU Düsseldorf, Düsseldorf, Germany, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²CHU Cochin, Paris, France, ¹³Hopital Robert Debré, Sérurier, France, ¹⁴CHU de Brest, Brest, France, ¹⁵AP-HP, Créteil, France, ¹⁶Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁷Inserm DR Paris 5, Paris, France, ¹⁸CHU de Caen, Caen, France, ¹⁹CHU la Réunion, La Réunion, France, ²⁰CHU Rennes, Rennes, France, ²¹UBO, Brest, France, ²²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ²³CH Bourgoin-Jallieu, Bourgoin-Jallieu, France, ²⁴CH Metz, Metz, France, ²⁵AP-HP, Paris, France, ²⁶Avicenne Hospital, Bobigny, France, ²⁷Rome Hospital, Rome, France, ²⁸Tours Hospital, Tours, France, ²⁹Saint Luc Hospital, Bruxelles, Belgium, ³⁰Hopital SAINT ANTOINE APHP, Paris, France, ³¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³²Limoges Hospital, Limoges, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…
Abstract Number: 0969 • ACR Convergence 2023
Tumor Necrosis Factor-α Inhibitors Reduces Obstructive Sleep Apnea in Patients with Juvenile Idiopathic Arthritis: A Population-based Cohort Study
Pin-Chia Huang¹, Katharine Ching Chung², Zachary S Peacock³ and Kevin Sheng-Kai Ma⁴, ¹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ²University of Pittsburgh Medical Center, Mckeesport, PA, ³Oral and Maxillofacial Surgery, Massachusetts General Hospital, Harvard School of Dental Medicine, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Tumor necrosis factor-α (TNF-α) plays a role in the pathogenesis of and serves as a biomarker for obstructive sleep apnea (OSA). Moreover, patients with…
Abstract Number: 0981 • ACR Convergence 2023
Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors
Aron Hjalti Bjornsson¹, Telma Thrastardottir², Bjorn Gudbjornsson³ and Thorvardur Love⁴, ¹Landspitali University Hospital and the University of Iceland, Reykjavík, Iceland, ²University of Iceland, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland
Background/Purpose: Infections are a known complication of disease-modifying therapy in rheumatic patients but have also been associated with the diseases being treated. Biosimilars have increased…
Abstract Number: 1069 • ACR Convergence 2023
Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)
Manush Sondhi¹, Rahul Vyas², Anuj Thakre² and Samina Hayat¹, ¹Louisiana State University, Shreveport, LA, ²LSU Health Science Center, Shreveport, LA
Background/Purpose: Tumor necrosis factor-alpha (TNF-α) inhibitors, a widely used class of biological immunomodulating agents targeting TNF-α, have revolutionized the treatment of various autoimmune and inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].